Eli Lilly and Company (NYSE:LLY) Stock Position Raised by Wiley BROS. Aintree Capital LLC

Wiley BROS. Aintree Capital LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 20.0% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 811 shares of the company’s stock after buying an additional 135 shares during the quarter. Wiley BROS. Aintree Capital LLC’s holdings in Eli Lilly and Company were worth $380,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Wellington Management Group LLP raised its holdings in shares of Eli Lilly and Company by 1.6% during the 1st quarter. Wellington Management Group LLP now owns 20,324,267 shares of the company’s stock valued at $6,979,760,000 after purchasing an additional 314,349 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 1.1% during the 1st quarter. Geode Capital Management LLC now owns 14,867,424 shares of the company’s stock valued at $5,094,159,000 after purchasing an additional 159,964 shares in the last quarter. Morgan Stanley raised its holdings in shares of Eli Lilly and Company by 44.1% during the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after purchasing an additional 3,691,436 shares in the last quarter. Norges Bank bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at $3,416,206,000. Finally, Moneta Group Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company by 102,752.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after purchasing an additional 5,440,731 shares in the last quarter. Institutional investors own 81.38% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 34,156 shares of Eli Lilly and Company stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $454.08, for a total transaction of $15,509,556.48. Following the completion of the transaction, the insider now directly owns 101,387,286 shares of the company’s stock, valued at approximately $46,037,938,826.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $546.51, for a total transaction of $327,906.00. Following the completion of the sale, the chief accounting officer now owns 5,378 shares in the company, valued at approximately $2,939,130.78. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 34,156 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $454.08, for a total transaction of $15,509,556.48. Following the sale, the insider now owns 101,387,286 shares of the company’s stock, valued at approximately $46,037,938,826.88. The disclosure for this sale can be found here. Insiders sold 1,010,309 shares of company stock valued at $21,095,701,670 in the last ninety days. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $0.85 during trading on Thursday, hitting $598.03. 848,603 shares of the company’s stock traded hands, compared to its average volume of 3,008,287. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.13 and a quick ratio of 0.87. The firm’s fifty day moving average price is $504.85 and its 200 day moving average price is $433.48. Eli Lilly and Company has a twelve month low of $296.32 and a twelve month high of $601.84. The company has a market cap of $567.71 billion, a PE ratio of 83.29, a PEG ratio of 2.36 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The firm had revenue of $8.31 billion during the quarter, compared to the consensus estimate of $7.58 billion. During the same period last year, the firm posted $1.25 EPS. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. Analysts forecast that Eli Lilly and Company will post 9.83 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 0.76%. The ex-dividend date was Monday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 62.87%.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent research reports. Argus raised their price target on shares of Eli Lilly and Company from $470.00 to $620.00 and gave the company a “buy” rating in a report on Tuesday, September 5th. The Goldman Sachs Group raised their target price on shares of Eli Lilly and Company from $385.00 to $470.00 and gave the company a “neutral” rating in a research note on Wednesday, August 9th. Truist Financial raised their target price on shares of Eli Lilly and Company from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Wednesday, August 9th. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $500.00 to $615.00 and gave the company an “overweight” rating in a research note on Tuesday, August 8th. Finally, 22nd Century Group reiterated a “maintains” rating on shares of Eli Lilly and Company in a research note on Tuesday, June 27th. One analyst has rated the stock with a sell rating, one has given a hold rating and twenty have given a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $532.78.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.